细胞与分子免疫学杂志
細胞與分子免疫學雜誌
세포여분자면역학잡지
2009年
11期
1023-1025,1028
,共4页
紫杉醇%卡铂%卵巢癌%化疗%免疫重建
紫杉醇%卡鉑%卵巢癌%化療%免疫重建
자삼순%잡박%란소암%화료%면역중건
paclitaxel%carboplatin%ovarian cancer%chemotherapy%immune reconstitution
目的:研究晚期卵巢癌患者一线化疗后免疫细胞数量和表型的动态变化, 探询化疗后机体是否存在免疫重建的动态过程, 为制定化疗联合免疫治疗方案提供实验依据.方法:选取术后行紫杉醇联合卡铂化疗的晚期卵巢上皮癌患者共13例, 采集化疗前(S_0)、化疗后5～7 d(S_1)、化疗后12～14 d(S_2)和化疗后25～28 d(S_3)外周血, 流式细胞术检测患者外周血中CD3~+、 CD4~+、 CD8~+细胞、 CD4~+CD25~+ Treg细胞的百分比及绝对数量, 并进一步分析CD4~+和CD8~+细胞中记忆细胞、原始细胞的比例.结果:在一个完整的化疗周期中, 淋巴细胞的总数量在化疗后S_1期下降至最低, S_2期即开始恢复, 到S_3期则已恢复到化疗前水平;CD3~+、 CD4~+、 CD8~+细胞及CD4~+CD25~+ Treg细胞的绝对数目均于S_1期降至最低点, 且与S_0期分别都有统计学差异;CD8~+细胞的比例于S_1期降至最低;CD4~+CD25~+ Treg细胞的比例于S_2期降至最低;CD4~+CD45RO~+和CD8~+CD45RO~+细胞的比例于S_2期升至最高, 而CD8~+CD45RA~+细胞的比例于S_2期最低.结论:紫杉醇联合卡铂诱发卵巢癌患者于化疗后5～7 d出现一过性淋巴细胞减少症, 之后开始产生淋巴细胞自稳性增生(免疫重建).免疫重建期可能是免疫治疗实施的最佳窗口期.
目的:研究晚期卵巢癌患者一線化療後免疫細胞數量和錶型的動態變化, 探詢化療後機體是否存在免疫重建的動態過程, 為製定化療聯閤免疫治療方案提供實驗依據.方法:選取術後行紫杉醇聯閤卡鉑化療的晚期卵巢上皮癌患者共13例, 採集化療前(S_0)、化療後5～7 d(S_1)、化療後12～14 d(S_2)和化療後25～28 d(S_3)外週血, 流式細胞術檢測患者外週血中CD3~+、 CD4~+、 CD8~+細胞、 CD4~+CD25~+ Treg細胞的百分比及絕對數量, 併進一步分析CD4~+和CD8~+細胞中記憶細胞、原始細胞的比例.結果:在一箇完整的化療週期中, 淋巴細胞的總數量在化療後S_1期下降至最低, S_2期即開始恢複, 到S_3期則已恢複到化療前水平;CD3~+、 CD4~+、 CD8~+細胞及CD4~+CD25~+ Treg細胞的絕對數目均于S_1期降至最低點, 且與S_0期分彆都有統計學差異;CD8~+細胞的比例于S_1期降至最低;CD4~+CD25~+ Treg細胞的比例于S_2期降至最低;CD4~+CD45RO~+和CD8~+CD45RO~+細胞的比例于S_2期升至最高, 而CD8~+CD45RA~+細胞的比例于S_2期最低.結論:紫杉醇聯閤卡鉑誘髮卵巢癌患者于化療後5～7 d齣現一過性淋巴細胞減少癥, 之後開始產生淋巴細胞自穩性增生(免疫重建).免疫重建期可能是免疫治療實施的最佳窗口期.
목적:연구만기란소암환자일선화료후면역세포수량화표형적동태변화, 탐순화료후궤체시부존재면역중건적동태과정, 위제정화료연합면역치료방안제공실험의거.방법:선취술후행자삼순연합잡박화료적만기란소상피암환자공13례, 채집화료전(S_0)、화료후5～7 d(S_1)、화료후12～14 d(S_2)화화료후25～28 d(S_3)외주혈, 류식세포술검측환자외주혈중CD3~+、 CD4~+、 CD8~+세포、 CD4~+CD25~+ Treg세포적백분비급절대수량, 병진일보분석CD4~+화CD8~+세포중기억세포、원시세포적비례.결과:재일개완정적화료주기중, 림파세포적총수량재화료후S_1기하강지최저, S_2기즉개시회복, 도S_3기칙이회복도화료전수평;CD3~+、 CD4~+、 CD8~+세포급CD4~+CD25~+ Treg세포적절대수목균우S_1기강지최저점, 차여S_0기분별도유통계학차이;CD8~+세포적비례우S_1기강지최저;CD4~+CD25~+ Treg세포적비례우S_2기강지최저;CD4~+CD45RO~+화CD8~+CD45RO~+세포적비례우S_2기승지최고, 이CD8~+CD45RA~+세포적비례우S_2기최저.결론:자삼순연합잡박유발란소암환자우화료후5～7 d출현일과성림파세포감소증, 지후개시산생림파세포자은성증생(면역중건).면역중건기가능시면역치료실시적최가창구기.
AIM: We investigated the numbers and proportions of lymphocyte subsets in advanced ovarian cancer patients undergoing chemotherapy, so as to identify whether there is immune reconstitution after chemotherapy, and seek rational chemo-immunotherapy strategies in ovarian cancer treatment. METHODS: Blood samples from each ovarian cancer patient were obtained before (S_0) and at day 5-7 (S_1), day 12-14 (S_2) and day 25-28 (S_3) after chemotherapy in 13 patients. Flow cytometry technique was employed to analyse the numbers, proportions of CD3~+, CD4~+, CD8~+, CD4~+CD25~+ Treg and memory-like phenotype lymphocyte subsets. RESULTS: Lymphopenia was observed at S1 after chemotherapy, but lymphocytes were found gradually recovered after S1. The numbers of CD3~+, CD4~+, CD8~+T cells and CD4~+CD25~+ Treg cells reduced to the lowest on S_1. The proportions of CD8~+ T cells and CD4~+CD25~+ Treg cells reduced to the lowest on S_1 and S_2 respectively. The proportions of CD45RO~+ memory T cells increased significantly on S2 while the proportion of CD8~+CD45RA~+ T cells decreased remarkably on S_2. CONCLUSION: Paclitaxel and carboplatin induce lymphopenia at day 5-7 after chemotherapy, then comes the temporary immune reconstitution. It probably turns out that the "window period" during immune reconstitution offers a best opportunity for cancer immunotherapy.
